Bristol Myers Squibb Strengths And Weaknesses

1491 Words 6 Pages
Bristol-Myers Squibb overall performance positions them as one of the world’s largest bio-pharmaceutical leader. The company business level, functional level and corporate level strategies assisted with overpowering their challenges. The qualitative research method conducted provides a generalized aspect of the company internal weakness, strengths, threats and opportunities the company encountered. The weaknesses shown occurs in the leadership and decision making due to loss of patent protection and decline in revenues. This analysis provides an action plan that would help the company strategically in maintaining a strong advantage. It gives recommendations and strategies that can be implemented within the company. In order for a company to sustain a competitive advantage there must be consistency and a continuous stream of operations. BMS is in a good financial and competitive position and is able to maintain it with the proper actions and …show more content…
The company focuses on the unmet medical needs of patients with serious diseases. Its product line includes chemically-synthesized drugs and biological products, which focus on areas like cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis (GlobalData, 2014). This research analyzed the internal weakness of Bristol-Myers Squibb. The internal weakness reveal losses in patent protection, lawsuits and decline in revenues due to a lack in leadership and poor managerial decision making. Research showed that BMS patent loss for some of its major seller drugs include Plavix, Abilify and Avapro lead to a huge plunge in revenues. In 2012, Avapro revenues decline by 17 percent to $17.6 billion (Hoovers, 2015). In comparison, Abilify accounted for about $1.54 billion in revenues the first nine months in 2014 (Trefis,

Related Documents